Vertex kidney disease drug faces infection risk scrutiny ahead of FDA decision

Vertex's kidney disease therapy is expected to receive FDA approval, with the agency's decision scheduled for Nov 30.

A previously undisclosed pause rule has drawn attention, raising concerns about infection risk and possible label implications for the drug.

The issue is being highlighted as kidney specialists convene at the American Society of Nephrology meeting, underscoring heightened interest from investors and analysts.